|
1.
|
National Institute of Health: PubMed
Health: Osteosarcoma. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002616/.
Accessed March 18, 2013. Last revised 10/2012.
|
|
2.
|
Kaste SC, Pratt CB, Cain AM, Jones-Wallace
DJ and Rao BN: Metastases detected at the time of diagnosis of
primary pediatric extremity osteosarcoma at diagnosis: imaging
features. Cancer. 86:1602–1608. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
American Cancer Society: Osteosarcoma:
What are the survival rates for osteosarcoma? http://www.cancer.org/cancer/osteosarcoma/detailedguide/osteosarcoma-survival-rates.
Accessed March 18, 2013. Last revised 01/17/2013.
|
|
4.
|
National Cancer Institute: Childhood Soft
Tissue Sarcoma Treatment (PDQ®). http://www.cancer.gov/cancertopics/pdq/treatment/child-soft-tissue-sarcoma/HealthProfessional/.
Accessed March 18, 2013. Last updated 12/3/2012.
|
|
5.
|
Patham DM: Pathologic classification of
rhabdomyosarcoma and correlations with molecular studies. Med
Pathol. 14:506–514. 2001. View Article : Google Scholar
|
|
6.
|
Mandell L, Ghavinni F, LaQuaglia M and
Exelby P: Prognostic significance of regional lymph node
involvements in childhood extremity rhabdomyosarcoma. Med Pediatr
Oncol. 18:466–471. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Koscielniak E, Rodary C, Flamant F, Carli
M, Treuner J, Pinkerton CR and Grono P: Metastatic rhabdomyosarcoma
and histologically similar tumors in childhood: a retrospective
European multi-center analysis. Med Pediatr Oncol. 20:209–214.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Benassi MS, Gamberi G, Magagnoli G,
Molendini L, Ragazzini P, Merli M, Chiesa F, Balladelli A, Manfrini
M, Bertoni F, Mercri M and Picci P: Metalloproteinase expression
and prognosis in soft tissue sarcomas. Ann Oncol. 12:75–80. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
10.
|
Liotta LA, Tryggvason K, Garbisa A, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion, metastasis and angiogenesis.
Surg Oncol Clin North Am. 10:383–392. 2001.PubMed/NCBI
|
|
12.
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Sato T, Sakai T, Noguchi Y, Takta M,
Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion
of human uterine cervical carcinoma cells by augmenting the
expression and activation of stromal matrix metalloproteinases.
Gynecol Oncol. 92:47–56. 2004. View Article : Google Scholar
|
|
14.
|
Pyke C, Kristensen P, Ralfkiaer E,
Gröndahl-Hansen J, Eriksen J, Blasi F and Danø K: Urokinase-type
plasminogen activator is expressed in stromal cells and its
receptor in cancer cells at invasive foci in human colon
adenocarcinomas. Am J Pathol. 138:1059–1067. 1991.PubMed/NCBI
|
|
15.
|
Harvey P, Clark IM, Jourand MC, Warn RM
and Edwards DR: Hepatocyte growth factor/scatter factor enhances
the invasion of mesothelioma cell lines and the expression of
matrix metal-loproteinases. Br J Cancer. 83:1147–1153. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Liu Z, Ivanoff A and Klominek J:
Expression and activity of matrix metalloproteases in human
malignant mesothelioma cell lines. Int J Cancer. 91:638–643. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Vincent MP, White LA, Schroen DJ, Benbow U
and Brinckerhoff CE: Regulating expression of the gene for matrix
metalloproteinase-1 (collagenase): mechanisms that control enzyme
activity, transcription and mRNA stability. Crit Rev Eukaryot Gene
Expr. 6:391–411. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Rutkowski P, Kaminska J, Kowalska M, Ruka
W and Steffen J: Cytokine and cytokine receptor serum levels in
soft tissue sarcoma patients: correlations with
clinico-pathological features and prognosis. Int J Cancer.
100:463–471. 2002. View Article : Google Scholar
|
|
19.
|
Himelstein BP, Asada N, Carlton MR and
Collins MH: Matrix metalloproteinase-9 (MMP-9) expression in
childhood osseous osteosarcoma. Med Pediatr Oncol. 31:471–474.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ferrari C, Benassi S, Ponticelli F,
Gamberi G, Ragazzini P, Pazzaglia L, Balladelli A, Bertoni F and
Picci P: Role of MMP-9 and its tissue inhibitor TIMP-1 in human
osteosarcoma: findings in 42 patients followed for 1–16 years. Acta
Orthop Scand. 75:487–491. 2004.PubMed/NCBI
|
|
21.
|
Bjornland K, Flatmark K, Pettersen S,
Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases
participate in osteosarcoma invasion. J Surg Res. 127:151–156.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Roebuck MM, Helliwell TR, Chaudhry IH,
Kalogrianitis S, Carter S, Kemp G, Ritchie DA, Jane MJ and Frostick
SP: Matrix metalloproteinase expression is related to angiogenesis
and histologic grade in spindle cell soft tissue neoplasms of the
extremities. Am J Clin Pathol. 123:405–414. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Diomedi-Carnassei F, Boldrini R, Rava L,
Donfrancesco A, Boglino C, Messina E, Dominici C and Callea F:
Different patterns of matrix metalloproteinase expression in
alveolar versus embryonal rhabdomyosarcoma. J Pediatr Surg.
39:1673–1679. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Ray JM and Stetler-Stevenson WG: The role
of matrix metal-loproteinase and their inhibitors in tumour
invasion, metastasis and angiogenesis. Eur Respir J. 7:2062–2072.
1994.PubMed/NCBI
|
|
25.
|
Apodaca G, Rutka JT, Bouhana K, Berens ME,
Giblin JR, Rosenblum ML, McKerrow JH and Banda MJ: Expression of
metalloproteinases and metalloproteinase inhibitors by fetal
astrocytes and glioma cells. Cancer Res. 50:2322–2329.
1990.PubMed/NCBI
|
|
26.
|
Linder C, Linder S, Munck-Wickland E and
Strander H: Independent expression of serum vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF) in
patients with carcinoma and sarcoma. Anticancer Res. 18(3B):
2063–2068. 1998.PubMed/NCBI
|
|
27.
|
Graeven U, Andre N, Achilles E, Zornig C
and Schmeigel W: Serum levels of vascular endothelial growth factor
and basic fibroblast growth factor in patients with soft-tissue
sarcoma. J Cancer Res Clin Oncol. 125:577–581. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Rutkowski P, Kaminska J, Kowalska M, Ruka
W and Steffen J: Cytokine and cytokine receptor serum levels in
adult bone sarcoma patients: correlations with local tumor extent
and prognosis. J Surg Oncol. 84:151–159. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Niedzwiecki A, Roomi MW, Kalinovsky T and
Rath M: Micronutrient synergy - a new tool in effective control of
metastasis and other key mechanisms of cancer. Cancer Metastasis
Rev. 29:529–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Roomi MW, Monterrey JC, Kalinovsky T,
Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a
nutrient mixture in human cancer cell lines: a correlation study.
Exp Oncol. 32:243–248. 2010.PubMed/NCBI
|
|
31.
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Comparative effects of EGCG, green tea and a
nutrient mixture on the patterns of MMP-2 and MMP-9 expression in
cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
|
|
32.
|
Rath M and Pauling L: Plasmin-induced
proteolysis and the role of apoprotein(a), lysine and synthetic
analogs. Orthomolecular Med. 7:17–23. 1992.
|
|
33.
|
Sun Z, Chen YH, Wang P, Zhang J, Gurewich
V, Zhang P and Liu JN: The blockage of high-affinity lysine binding
sites of plasminogen by EACA significantly inhibits
prourokinase-induced plasminogen activation. Biochem Biophys Acta.
1596:182–192. 2002.PubMed/NCBI
|
|
34.
|
Valcic S, Timmermann BN, Alberts DS,
Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect
of six green tea catechins and caffeine on the growth of four
selected human tumor cell lines. Anticancer Drugs. 7:461–468. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Mukhtar H and Ahmed N: Tea polyphenols:
prevention of cancer and optimizing health. Am J Clin Nutr.
71:S1698–S1702. 2000.PubMed/NCBI
|
|
36.
|
Yang GY, Liao J, Kim K, Yurtow EJ and Yang
CS: Inhibition of growth and induction of apoptosis in human cancer
cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Taniguchi S, Fujiki H, Kobayashi H, Go H,
Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin
gallate, the main constituent of green tea, on lung metastasis with
mouse B16 melanoma cell lines. Cancer Lett. 65:51–54. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Hara Y: Green Tea: Health Benefits and
Applications. Marcel Dekker; New York, NY: 2001, View Article : Google Scholar
|
|
39.
|
Kawakami S, Kageyama Y, Fujii Y, Kihara K
and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion
and MMP 9 production of T24 human bladder cancer cells. Anticancer
Res. 21:213–219. 2001.PubMed/NCBI
|
|
40.
|
Morini M, Cai T, Aluigi MG, Noonan DM,
Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The
role of the thiol N-acetyl cysteine in the prevention of tumor
invasion and angiogenesis. Int J Biol Markers. 14:268–271.
1999.PubMed/NCBI
|
|
41.
|
Yoon SO, Kim MM and Chung AS: Inhibitory
effects of selenite on invasion of HT 1080 tumor cells. J Biol
Chem. 276:20085–20092. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Naidu KA, Karl RC and Coppola D:
Antiproliferative and proapoptotic effect of ascorbyl stearate in
human pancreatic cancer cells: association with decreased
expression of insulin-like growth factor 1 receptor. Dig Dis Sci.
48:230–237. 2003. View Article : Google Scholar
|
|
43.
|
Anthony HM and Schorah CJ: Severe
hypovitaminosis C in lung-cancer patients: the utilization of
vitamin C in surgical repair and lymphocyte-related host
resistance. Br J Cancer. 46:354–367. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Maramag C, Menon M, Balaji KC, Reddy PG
and Laxmanan S: Effect of vitamin C on prostate cancer cells in
vitro: effect on cell number, viability and DNA synthesis.
Prostate. 32:188–195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Koh WS, Lee SJ, Lee H, Park C, Park MH,
Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH:
Differential effects and transport kinetics of ascorbate
derivatives in leukemic cell lines. Anticancer Res. 8:2487–2493.
1998.PubMed/NCBI
|
|
46.
|
Chen Q, Espey MG, Krishna MC, Mitchell JB,
Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic
ascorbic acid concentrations selectively kill cancer cells: action
as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl
Acad Sci USA. 102:13604–13609. 2005. View Article : Google Scholar
|
|
47.
|
Nunez C, Ortiz de Apodaca Y and Ruiz A:
Ascorbic acid in the plasma and blood cells of women with breast
cancer. The effect of consumption of food with an elevated content
of this vitamin. Nutr Hosp. 10:368–372. 1995.PubMed/NCBI
|
|
48.
|
Kurbacher CM, Wagner U, Kolster B,
Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C)
improves the antineo-plastic activity of doxorubicin, cisplatin and
paclitaxel in human breast carcinoma cells in vitro. Cancer Lett.
103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Cooke JP and Dzau VJ: Nitric oxide
synthase: Role in the genesis of vascular disease. Annu Rev Med.
48:489–509. 1997. View Article : Google Scholar : PubMed/NCBI
|
